Literature DB >> 96213

The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects.

M C Stephens, A Bernatsky, V Burachinsky, G Legler, J N Kanfer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 96213     DOI： 10.1111/j.1471-4159.1978.tb12395.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN： 0022-3042            Impact factor:   5.372


× No keyword cloud information.
  12 in total

1.  Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.

Authors:  U H Schueler; T Kolter; C R Kaneski; G C Zirzow; K Sandhoff; R O Brady
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

2.  Glucosylceramide and the level of the glucosidase-stimulating proteins.

Authors:  S C Datta; N S Radin
Journal:  Lipids       Date:  1986-11       Impact factor: 1.880

3.  Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease.

Authors:  W M Holleran; E I Ginns; G K Menon; J U Grundmann; M Fartasch; C E McKinney; P M Elias; E Sidransky
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

4.  β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.

Authors:  Christina M Ridley; Karen E Thur; Jessica Shanahan; Nagendra Babu Thillaiappan; Ann Shen; Karly Uhl; Charlotte M Walden; Ahad A Rahim; Simon N Waddington; Frances M Platt; Aarnoud C van der Spoel
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

5.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

6.  L-glucosylceramide: synthesis, properties, and resistance to catabolism by glucocerebrosidase in vitro.

Authors:  A E Gal; P G Pentchev; J M Massey; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

7.  Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function.

Authors:  W M Holleran; Y Takagi; G K Menon; G Legler; K R Feingold; P M Elias
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Characterization of the phospholipid requirement of a rat liver beta-glucosidase.

Authors:  A Basu; R H Glew
Journal:  Biochem J       Date:  1984-12-01       Impact factor: 3.857

Review 9.  Animal models for Gaucher disease research.

Authors:  Tamar Farfel-Becker; Einat B Vitner; Anthony H Futerman
Journal:  Dis Model Mech       Date:  2011-10-04       Impact factor: 5.758

10.  CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.

Authors:  John Marshall; Ying Sun; Dinesh S Bangari; Eva Budman; Hyejung Park; Jennifer B Nietupski; Amy Allaire; Mary A Cromwell; Bing Wang; Gregory A Grabowski; John P Leonard; Seng H Cheng
Journal:  Mol Ther       Date:  2016-03-07       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.